Ser803
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser803  -  ERK5 (human)

Site Information
QREIQMDsPMLLADL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 20572701

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 ) , mutation of modification site ( 4 )
Disease tissue studied:
breast cancer ( 2 ) , breast ductal carcinoma ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:
breast ( 1 , 2 ) , HeLa (cervical) ( 4 )

Upstream Regulation
Treatments:
nocodazole ( 4 ) , sorbitol ( 4 )

Downstream Regulation
Effects of modification on ERK5:
enzymatic activity, inhibited ( 4 ) , intracellular localization ( 4 )
Effects of modification on biological processes:
transcription, altered ( 4 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

3

Gilley R, et al. (2012) CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIM(EL). Cell Signal 24, 170-80
21924351   Curated Info

4

IƱesta-Vaquera FA, et al. (2010) Alternative ERK5 regulation by phosphorylation during the cell cycle. Cell Signal 22, 1829-37
20667468   Curated Info